Anti-Clotting Drug Apixaban Receives NICE Approval

British drug regulator National Institute for Health and Clinical Excellence (NICE) has approved the use of the anti-clotting drug

British drug regulator National Institute for Health and Clinical Excellence (NICE) has approved the use of the anti-clotting drug manufactured by Pfizer and Bristol-Meyers, apixaban, in preventing blood clots post hip and knee surgery.

NICE said that apixaban, which is being marketed under the brand name Eliquis, was a cost effective and clinically effective option in treating blood clots.

Anticoagulation Therapy / Blood Thinners - Injectable - Oral - Indications
Anticoagulants prevent the clotting of blood in our body. They are administered orally or via injection.

The treatment for knee replacement patients will last for 12 days and will cost around £41.16 while it will last for 34 days for hip replacement patients and will cost £116.62.

Source-Medindia

Deep Vein Thrombosis (DVT) - Causes - Symptoms - Diagnosis - Treatment - Complications - Prevention
A blood clot (thrombus) in the deep venous system of the leg leads to deep vein thrombosis (DVT). DVT is a major cause of morbidity and mortality.

Seated Immobility Causes Deep Vein Thrombosis (DVT)
People who sit for long hours without moving are said to be more prone to deep vein thrombosis (DVT).